seed agar (PSA). The C. albicans and bacterial plates were incubated overnight at 37°C and the T. mentagrophytes plates for 3 days at 30°C.
In vivo protection data were obtained using albino male mice weighing 18-20g infected with C. albicans, E. coli or K. pneumoniae.
In the case of C. albicans 759, mice were infected intravenously (0.2 ml) with a saline suspension of an 18-hour SABOURAUD'S glucose agar culture (approximately 2 x 108 cells/mouse). The mice were treated subcutaneously, one and five hours post-infection, and the EDoo values, expressed as total dose, were calculated by the method of LITCHFIELD and WILCOxoNS'. The bacterial infection-protection tests and the pharmacokinetic studies (serum levels, urinary excretion) were performed using procedures described previous-
Results Results
In Vitro Studies
The in vitro activities against T. mentagrophytes 1258 for the cephalosporins and several controls are summarized in Table 1 . Activities against C. albicans 759 are shown in Table 2 , and against the four yeast strains in Table 3 .
Of the four cephalosporins with the 2-pyridinethiol 1-oxide substituent at the 3'-position , those with a phenylglycine side chain at the 7-position (3, 4) exhibited the best activity against T. mentagrophytes . The mandeloyl derivative (2) was less active and the thienylacetyl derivative (1) essentially inactive against this organism. Cephalosporin 5 which contains the 2-pyridinethiol 1-oxide moiety in the acyl side chain is inactive against T. mentagrophytes. None of the cephalosporins were as active in vitro as the three antifungal controls (omadine, griseofulvin, tolnaftate).
The activity against Candida albicans (Table 2) follows the same order of potency observed with T .
mentagrophytes, however, the inhibition zones are consistently larger. In many cases double inhibition zones were observed with a well-defined inner zone surrounded by a hazy outer zone. Again compound 5 was virtually without activity. In this case, the activities exhibited by cephalosporins 1 -4 compare more favorably with those of the antifungal controls.
Against the four yeast strains, all four cephalosporins with the 2-pyridinethiol 1-oxide side chain at the 3'-position possess basically the same pattern of activity as against C. albicans (Table 3) . The strains showed different degrees of sensitivity; Pichia pines was the most sensitive and the Kloeckeria sp .
the least sensitive. Compound 4 was the most potent against all strains on all three media. Compound 5 was inactive. Omadine proved to be more potent against these yeast strains than either nystatin or amphotericin B.
Compound 4 also was compared with omadine, amphotericin B, cefazolin and cephalexin in an agar dilution assay using C. albicans. The MIC value for 4 was only one dilution less than that of omadine (12.5 versus 6.3,ug/ml). As expected, amphotericin B was more active (0.21tg/ml) and the two known Table 4 show the in vitro activities of the five cephalosporins and those of omadine, cefazolin and cephalexin against 15 standard strains of bacteria"'. All of the test cephalosporins have broad spectrum antibacterial activities comparable to those of omadine, cefazolin and cephalexin.
In Vivo Studies
Although all four cephalosporins containing the 2-pyridinethiol 1-oxide at the 3'-position were found to possess in vitro antifungal activity, none of them protected or prolonged survival time of mice experimentally infected with C. albicans (EDso?200mg/kg), whereas, amphotericin B gave good protective activity (EDso=0.08 mg/kg). In contrast to this finding, all these cephalosporins protected mice against experimental systemic infections with Escherichia coli and Klebsiella pneumoniae ( Table 5 ). The subcutaneous EDso values are best for 5 and 4 and the poorest for 1. Oral administration of compound 4 produced some protection in both infections. Omadine, when injected subcutaneously, was not pro-
The pharmacokinetic behavior of these cephalosporins was in agreement with the mouse protection (8) 8 ( data. Peak serum concentrations in mice (20 mg/kg subcutaneously) were 27, 11 and 24 //g/ml for compounds 1, 3 and 4, respectively. Oral administration of the phenylglycine analogs resulted in only trace serum levels and low urinary excretion, although they protected mice at high dose levels.
This phenomenon has been observed in our laboratory with other phenylglycine cephalosporins.
GOTTSTEIN et al. reported that N-benzyldithiocarbamoylacetamido-cephalosporanic acid had in vitro antifungal activity4).
Additional semisynthetic cephalosporins with in vitro antifungal activities are described here.
The antifungal activity of one of these cephalosporins (compound 2) previously has been reported by O'CALLAGHAN et al9). These cephalosporins incorporate a 2-pyridinethiol 1-oxide Discussion Not tested moiety at the 3'-position. Antifungal activity was not observed when this moiety is a part of the 7-substituent. The cephalosporin described by GOTTSTEIN et al. 4 ) is a dithiocarbamate and thus might be expected to have antifungal activity per se. O'CALLAGHAN et al. 8, 9) have demonstrated that one of the cephalosporins described here (compound 2) releases omadine (an antifungal agent in itself) under conditions of //-lactam ring opening. The data of GREENWOOD and O'GRADY support this finding"). Our data also tends to support this assumption with the exception of the activity versus C. albicans where the antifungal activities of the cephalosporins are equal to or greater than that of omadine ( Table 2 ). The antimicrobial activity of omadine is due to its chelate-formation with cations2). With copper, it immediately forms a greenish-brown water-insoluble complex. None of the cephalosporins with this side chain showed complex formation upon the addition of copper sulfate. Although this would tend to suggest that omadine was not released from the molecule, the study was not carried out under the in vitro antifungal test conditions. In any case, neither of these cephalosporin types are active against Candida infections in laboratory animals. In the case of these cephalosporins, it may be that the antifungal agent, whatever it is, may not reach high enough concentration at the site of infection. This is especially likely if omadine is the sole active factor as it failed to protect mice infected with C. albicans. Although the intact cephalosporins were capable of producing protective antibacterial blood levels in mice, they failed to protect against C. albicans infection as did omadine itself. The 2-pyridinethiol 1-oxide side chain is still of some research interest in that this grouping has been attached at the 3'-position to a cephamycin nucleus; however, no antifungal data was reported with this compound10). Other reports of similar 1-oxide side chains attached to a /3-lactam nucleus are available but no biological data has been reported for these compounds".
